SCHEMBL586319

SCHEMBL586319

COc1cc(Cl)cc(CO)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.43
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
MARS1 P56192 2/20 0.41
ALDH1A1 P00352 2/20 0.40
FFAR4 Q5NUL3 1/20 0.39
MAPT P10636 1/20 0.39
CALM1 P0DP23 1/20 0.38
AKR1B1 P15121 1/20 0.38
THRB P10828 1/20 0.38
RORC P51449 1/20 0.38
CNR1 P21554 1/20 0.38
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
PTGS2 P35354 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL586588 0.85 MARS1 (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1621101 0.84 DAO (0.53) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL65276 0.84 ALDH1A1 (0.58) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL28123040 0.82 ALDH1A1 (0.55) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL12221468 0.82 APP (0.49) ALDH1A1MAPTCALM1
SCHEMBL8223455 0.81 PTGS2 (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL16959931 0.80 MAPT (0.39) ALDH1A1MAPTCYP4F2CYP4A11
SCHEMBL18860620 0.80 MAPT (0.43) FFAR4MAPTCYP4F2CYP4A11
SCHEMBL3086949 0.79 GRIN2D (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3933664 0.79 MARS1 (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559582-B2 Polyacrylate polymer BASF SE (DE) 2026-02-24 US claimed
EP-3898730-A1 POLYACRYLATE POLYMER BASF SE (DE) 2021-10-27 EP claimed
CN-113195564-A Polyacrylate polymers 巴斯夫欧洲公司 2021-07-30 CN claimed
WO-2020127463-A1 POLYACRYLATE POLYMER BASF SE (DE) 2020-06-25 WO claimed
EP-2044063-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Astra Zeneca AB (SE) 2009-04-08 EP claimed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 WO claimed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 US claimed
US-12559582-B2 Polyacrylate polymer BASF SE (DE) 2026-02-24 US disclosed
EP-3768269-B1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2025-08-20 EP disclosed
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 US disclosed
CN-118084800-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-118084801-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-117964834-A Polyacrylate polymers 巴斯夫欧洲公司 2024-05-03 CN disclosed
WO-2004058164-A2 ASTHMA AND ALLERGIC INFLAMMATION MODULATORS TULARIK, INC. (US) 2004-07-15 WO disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
EP-0781126-B1 DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM ZAMBON SPA (IT) 2001-12-12 EP disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed
US-5674909-A FOR TREATMENT OF CARDIOVASCULAR DISORDERS ZAMBON GROUP (IT) 1997-10-07 US disclosed
EP-0781126-A2 DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM ZAMBON GROUP S.p.A. (IT) 1997-07-02 EP disclosed
WO-1996008228-A2 DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM ZAMBON GROUP S.P.A. (IT) 1996-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559582-B2 Polyacrylate polymer SAAL1, ATXN2L, VCL DAO 1580/4885GRIN2D 2191/4885GRIN3B 4267/4885
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 DAO 1167/4885GRIN2D 149/4885GRIN3B 48/4885
US-20080004302-A1 Novel Compounds CYP11B2, CYP11B1, CYP46A1 DAO 4285/4885GRIN2D 3757/4885GRIN3B 2287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.